Physician profile
Trupti Shinde
NPI 1437425790
$2,660.72
in general payments reported to CMS, 2019-2025
27 companies · $669 in 2025
The $669 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $41.98 · 2021: $474 · 2022: $393 · 2023: $438 · 2024: $519 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $682.39 | 2019-2025 | Linzess, Viberzi, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $288.54 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $197.01 | 2025 | Livdelzi |
| E.R. Squibb & Sons, L.L.C. | $167.48 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $152.63 | 2024-2025 | Voquezna |
| Medtronic, INC. | $143.89 | 2023-2024 | Endoflip, Nexpowder |
| Lilly USA, LLC | $125.00 | 2024 | Omvoh |
| Boston Scientific Corporation | $115.13 | 2022-2024 | Watchman Flx |
| Fujifilm Healthcare Americas Corporation | $99.82 | 2022-2023 | Fujifilm |
| Celgene Corporation | $94.06 | 2022-2023 | Zeposia |
| Pfizer INC. | $78.34 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $66.86 | 2021-2023 | |
| Janssen Biotech, INC. | $63.47 | 2021-2023 | Stelara |
| Aimmune Therapeutics, INC. | $49.48 | 2024 | |
| Genzyme Corporation | $43.39 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.47 | 2023-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $33.33 | 2025 | Rezdiffra |
| Novo Nordisk INC | $32.10 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $29.13 | 2024 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $28.18 | 2024 | Dupixent |
| Endogastric Solutions, INC | $25.65 | 2024 | Esophyx |
| Amag Pharmaceuticals, INC. | $21.02 | 2021 | |
| Ucb, INC. | $20.75 | 2022 | |
| Ardelyx, INC. | $19.41 | 2024 | Ibsrela |
| Exact Sciences Corporation | $15.56 | 2023 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $15.52 | 2024 | Rebyota |
| Allergan, INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trupti Shinde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.